In prodromal Alzheimer’s disease and mild cognitive impairment: Beyond the ability to discriminate AD dementia patients from CN subjects, a major challenge for tau radiotracers is their efficacy as early biomarkers, that is, their use as a sensitive tool for detecting early stages of AD tau pathology. The gene discussed is MAPT; the disease is Alzheimer disease.